43 results
Biologic Events Leading to Chronic GVHD #Pathophys #Honc #Pharm #GVHD #GraftVersusHostDisease #Therapeutic #Pathways #NEJM
GVHD #Pathophys #Honc ... #Pharm #GVHD #GraftVersusHostDisease ... Therapeutic #Pathways #NEJM
Progression-free Survival  #EBM #Honc #Osimertinib #NSCLC #Survival #NEJM
Survival #EBM #Honc ... #Osimertinib #NSCLC ... #Survival #NEJM
Signaling Mechanism of PD-1 and PD-L1 and Inhibition of PD-1 Signaling in Microsatellite-Instability–High Cancers. MHC1 denotes
Pathophysiology #Honc ... #Pharm #PD1 #PDL1 ... MicrosatelliteInstability #NEJM
Early Events in Acute GVHD #Pathophys #Honc #GVHD #GraftVersusHostDisease #NEJM
GVHD #Pathophys #Honc ... GraftVersusHostDisease #NEJM
Alectinib versus Crizotinib in Untreated ALK-Positive Non–Small-Cell Lung Cancer #EBM #Honc #Alectinib #Crizotinib #ALK #ALKPositive #NSCLC
Lung Cancer #EBM #Honc ... #ALKPositive #NSCLC ... VisualAbstract #NEJM
Possible Mechanisms Underlying Immune-Related Adverse Events #Pathophys #Honc #ImmuneRelatedAdverseEvents #Immunotherapy #NEJM
Events #Pathophys #Honc ... Immunotherapy #NEJM
Role of G6PD in Protection against Oxidative Damage #Pathophys #Peds #Genetics #Honc #Favism #g6pd #NEJM
Peds #Genetics #Honc ... #Favism #g6pd #NEJM
The Pathway of Heme Synthesis, Showing Pathway Intermediates and End-Product Regulation by Heme #Pathophys #Honc #Heme
Heme #Pathophys #Honc ... Synthesis #Porphyria #NEJM
Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer - Progression-free Survival in the Intention-to-Treat Population.
#EBM #Honc #PACIFIC ... #Durvalumab #NSCLC ... #NEJM
An AAV5 vector with a functional factor VIII gene tested in men with hemophilia A #EBM
hemophilia A #EBM #Honc ... VisualAbstract #NEJM